checkAd

    GLIF-Grant Life Sciences-BOMBENNEWS - 500 Beiträge pro Seite

    eröffnet am 11.09.06 18:37:13 von
    neuester Beitrag 12.09.06 13:48:43 von
    Beiträge: 6
    ID: 1.081.682
    Aufrufe heute: 0
    Gesamt: 9.185
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 11.09.06 18:37:13
      Beitrag Nr. 1 ()
      Grant Life Sciences Receives Purchase Order from India for Two Million Point-of-Care (POC), \'Rapid\' Malaria Tests to Be Delivered by Year-End
      9/11/2006
      LOS ANGELES, Sep 11, 2006 (BUSINESS WIRE) --

      \"This is an important event, because it demonstrates that we are successfully executing our new corporate strategy, part of which is to drive sales through our established marketing channels overseas.\"

      Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences

      Grant Life Sciences Inc. (OTC BB: GLIF) announced today that it has received a purchase order from an arm of the Indian government for two million of its point-of-care (POC), \'rapid\' malaria tests, to be delivered by year-end. Grant intends to ship approximately 25 percent of the total order immediately. These malaria tests are part of the \'AccuDx\' rapid-test product line to which Grant holds exclusive rights from AccuDx Corp.--a biotechnology company founded by Ravi Pottathil, Ph.D., one of the world\'s leading authorities in the field of HIV/AIDS diagnostics and therapeutics. The AccuDx portfolio includes additional rapid tests for HIV-1, HIV-2, for example, and Dengue Fever.

      \"When we acquired exclusive rights to the AccuDx rapid-test portfolio, we said that we expected to generate revenues from these products in specialty diagnostic markets outside of the United States,\" said Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences. \"Certainly, this sizable order from India bears strong testimony to the opportunities ahead of us. Indeed, this order demonstrates that we are making considerable progress toward executing our new corporate strategy: (1) to acquire new products and technologies via in-licensing activities; (2) out-license products for further development and sales; and (3) drive sales through our established marketing channels--as is the case with this significant order from India,\" said Dr. Lin.

      About Grant Life Sciences, Inc.

      Grant Life Sciences, a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women\'s health, infectious diseases, and cancers.

      Forward-Looking Safe Harbor Statement

      With the exception of historical information, the matters discussed in this press release are \"forward-looking statements\" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company\'s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company\'s products. In some cases, \"forward-looking statements\" can be identified by terminology such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or \"continue,\" or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the \"forward-looking\" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such \"forward-looking statements\" will be achieved. Grant Life Sciences undertakes no duty to update any of the \"forward-looking statements,\" whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such \"forward-looking statements.\" For further risk factors associated with our Company, review our SEC filings.

      SOURCE: Grant Life Sciences

      Grant Life Sciences Don Rutherford, 949-521-1232
      Copyright Business Wire 2006
      Avatar
      schrieb am 11.09.06 18:40:39
      Beitrag Nr. 2 ()
      jup ab gehts.
      :laugh::laugh:
      Avatar
      schrieb am 11.09.06 19:39:55
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 23.878.166 von axcol am 11.09.06 18:40:39:eek:
      Avatar
      schrieb am 11.09.06 19:41:55
      Beitrag Nr. 4 ()
      Avatar
      schrieb am 12.09.06 05:21:30
      Beitrag Nr. 5 ()
      :yawn::rolleyes::rolleyes:

      Trading Spotlight

      Anzeige
      JanOne
      3,3600EUR -15,37 %
      Die nächste 700% NASDAQ-Crypto-Chance? mehr zur Aktie »
      Avatar
      schrieb am 12.09.06 13:48:43
      Beitrag Nr. 6 ()
      wow! :eek:

      das ding ist ja krass!!!




      demnächst könnte USB:ECCI starten.

      Schaut doch mal hier vorbei!

      Thread: Hinweis auf SUPER Hurrikan-Turbo-Aktie !!

      Hatte GLIF schon ewig auf meiner Watch aber bin nicht eingestiegen ich idiot!

      Evtl. mache ich es ja bei ECCI besser!


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      GLIF-Grant Life Sciences-BOMBENNEWS